|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:1998
gptkb:FDA
|
|
gptkbp:bioavailability
|
Avsola
Inflectra
Renflexis
|
|
gptkbp:brand
|
infliximab
|
|
gptkbp:class
|
gptkb:immunotherapy
gptkb:monoclonal_antibody
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
heart failure
active infections
hypersensitivity to infliximab
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:formulation
|
lyophilized powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Remicade
|
|
gptkbp:indication
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
gptkb:ankylosing_spondylitis
psoriasis
|
|
gptkbp:ingredients
|
infliximab
|
|
gptkbp:invention
|
gptkb:2018
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
tuberculosis screening
|
|
gptkbp:manufacturer
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
TNF-alpha inhibitor
|
|
gptkbp:patient_education
|
informed consent required
monitor for signs of infection
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:pharmacokinetics
|
dose-dependent clearance
half-life of 8 to 10 days
inhibition of TNF-alpha
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_guidance_on
|
recommended for severe cases
used in combination with methotrexate
|
|
gptkbp:requires
|
available online
|
|
gptkbp:research
|
clinical studies
off-label uses
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:service_frequency
|
every 6 to 8 weeks
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
infections
autoimmune disorders
infusion reactions
serious infections
malignancies
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:used_for
|
treatment of autoimmune diseases
|
|
gptkbp:bfsParent
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:bfsLayer
|
4
|